Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Hodgkin lymphoma’s (HL) tumor composition is characterized by a paucity of malignant cells and a preponderance of immune and stromal cells. Despite the rich immune milieu within the tumor microenvironment, malignant cells are able to effectively evade the immune system and use immune support to promote lymphoma cell growth and proliferation. Recognizing this has led to the identification of checkpoint inhibitory signals that enable immune evasion and to opening the door to therapeutic strategies on how to exploit the immune system in targeting tumor cells. We discuss herein some of the tumor evasion mechanisms in HL with a particular focus on the immune checkpoint pathways and focus on recent clinical data of checkpoint blockade in HL treatment.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalExpert Review of Clinical Immunology
StateAccepted/In press - Feb 17 2016


  • checkpoint blockade
  • CTLA4
  • Hodgkin Lymphoma
  • Immunotherapy
  • PD-1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma'. Together they form a unique fingerprint.

Cite this